The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | C | Cardiovascular system | |
| 2 | C01 | Cardiac therapy | |
| 3 | C01C | Cardiac stimulants excl. cardiac glycosides | |
| 4 | C01CX | Other cardiac stimulants |
| Code | Title | |
|---|---|---|
| C01CX06 | Angiotensinamide | |
| C01CX07 | Xamoterol | |
| C01CX08 | Levosimendan | |
| C01CX09 | ||
| C01CX10 |
| Active Ingredient | Description | |
|---|---|---|
| Angiotensin II |
Angiotensin II raises blood pressure by vasoconstriction; increased aldosterone release via direct action of angiotensin II on the vessel wall is mediated by binding to the G-protein-coupled angiotensin II receptor type 1 on vascular smooth muscle cells which stimulates Ca2+/calmodulindependent phosphorylation of myosin and causes smooth muscle contraction. |
|
| Levosimendan |
Levosimendan enhances the calcium sensitivity of contractile proteins by binding to cardiac troponin C in a calcium-dependent manner. Levosimendan increases the contraction force but does not impair ventricular relaxation. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| GIAPREZA Concentrate for solution for infusion | European Medicines Agency (EU) | MPI, EU: SmPC | |
| GIAPREZA Solution for injection | FDA, National Drug Code (US) | MPI, US: SPL/PLR | |
| SIMDAX Injection | Medicines and Medical Devices Safety Authority (NZ) | MPI, EU: SmPC |
